Biotimize
During the past decade, a significant shift has been seen in the nature of the products manufactured and sold by the innovative biopharmaceutical industry. The global biopharmaceutical portfolio of today contains a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise in treatments for many orphan diseases. These trends have increased the number of biopharmaceutical products with extremely limited production runs, highly specific manufacturing requirements, and genotype-specific products (1).
Biopharmaceuticals treat and prevent some of the most prevalent and debilitating diseases that affect human health, including cancer, diabetes, autoimmune disorders, and bacterial and viral infections. It resulted in one of the most valuable and important business sectors in the world. Unlike other medicines, biopharmaceuticals are manufactured in, extracted, or otherwise derived from biological sources and require complex raw materials, equipment and manufacturing processes, and extremely highly specialized labor and facilities (2).
The most biological manufacturing capacity is allocated in North America and Europe. South America represents only 2.19% of world biopharmaceutical manufacturing capacity (3). It helps to explain the low number of biopharmaceutical products launched through Brazilian research, for example (4). The low manufacturing capacity also implies in a high cost of healthcare expenditures by Brazilian government, what reached 1.3 billion USD in 2015 (5).
Other reasons for this outlook are the need for pilot-scale facilities and training in the bioprocess industrial environment. Pilot-scale facilities are essential for the risk-reduction process of projects, since it explores challenges not found in laboratory-scale studies. Moreover, the lack of suitable bioprocess infrastructure for training prevents graduates to fill key industrial positions, such as those involved in cell culture and fermentation, downstream processes, analytical development, scale-up, and regulatory affairs (6).
One option to mitigate the high cost and risk of developing and manufacturing biopharmaceuticals is to partner with Contract Development and Manufacturing Organizations (CDMO). CDMOs are facilities specializing in the development and manufacturing of complex biologics for clinical and commercial stages. These facilities operate under GMP regulation and can provide third parties with access to high quality infrastructure with lower risk and investment, as well as apply their scientific and technical knowledge to serve as a useful strategy in the development and manufacture of biopharmaceuticals. (6). Curiously, there are more than 500 biological CDMO around the world, holding ~3.5 million liters of capacity (19.8% of that worldwide) at an average of 6,715 L/facility (7).
Facing the biological manufacturing gap that exists in Brazil, the Biotimize is building the first biological CDMO in the country. “For us, it will be a grateful accomplishment to be tool that will accelerate innovations of biological products by Brazilian companies”, says Fernando Barbosa, CEO of Biotimize. “More than that, we believe that we can democratize access to science and healing through our facilities, making a positive impact on people lives and bringing independence to developing countries”.
(2) https://niimbl.force.com/s/about-niimbl
(3) Top1000bio.com
(4) https://consultas.anvisa.gov.br/#/medicamentos
(5) http://repositorio.ipea.gov.br/bitstream/11058/8522/1/TD_2398.pd
In our last post, we talked about the CDMO importance (Why do we need a CDMO?). Now that it is clear, we need to understand what the key considerations are to choose the right CDMO for your process. Choosing a CDMO is something highly strategic and delicate, since the wrong choice can negatively impact the… Continue reading How to select the best CDMO for your needs?
Democratizing Access to Science: The Crucial Role of Contract Development and Manufacturing Organizations (CDMOs) in South America In the pursuit of global progress, the democratization of access to science stands as a pivotal objective. Contract Development and Manufacturing Organizations (CDMOs) have emerged as potent facilitators in this endeavor, playing a vital role in advancing scientific… Continue reading The Crucial Role of CDMOs in South America
Biotimize - Biotechnology as a Service is committed to complying with the laws that protect the privacy of the data of its employees, partners and the general public.
See how we deal with the information collected:
What are the data types?
Personal data:
”Information related to the identified or viral person”, for example: first name, last name, date of birth, personal documents, home or business address, telephone, email and IP address.
Sensitive Personal data:
These are the data that refer to racial or ethnic origin, religious conviction, political opinion, union affiliation or organization of a religious, philosophical or political nature. Sensitive personal data as well are those related to health or sex life, genetic or biometric data.
What data does our Company collect?
Our company handles data from employees, partners and service providers, being duly compliant with the LGPD.
On the website, the company collects data through the voluntary and consensual completion of forms, e-books and contact to receive the newsletter.
Is there automatic data collection? Biotimize - Biotechnology as a Service does not automatically collect data in each access to the website.
How do they use my data?
The personal data provided by users who fill in the forms are used solely to provide feedback at the user's request (individual or legal entity interested in our company's products and services).
Once the service is completed, such data is deleted.
Have you got any questions?
Talk to the Data Protection Manager (DPO) by email: dpo@biotimize.com.br
You will be able to clarify doubts related to the processing of personal data.
